Kimberly-Clark seeks EU approval for Kenvue deal
Kimberly-Clark has officially requested regulatory approval from the European Union for its proposed forty billion dollar acquisition of Tylenol maker Kenvue. The major merger aims to combine massive consumer health portfolios and generate significant annual cost savings.
Xurve View
Insights:
Xurve View
KIMBERLY-CLARK CORP filed for EU antitrust clearance for its $40 billion acquisition of KENVUE INC during the morning. The proposed merger unites consumer health brands like Tylenol with Kimberly-Clark's global tissue portfolio. The transaction ranks among the largest consumer goods combinations in recent years, reshaping the sector ahead of a planned 2026 completion.
